Finerenone (BAY 94-8862) is a nonsteroidal mineralocorticoid receptor antagonist 
in development for the treatment of diabetic kidney disease. This observational 
trial compared the pharmacokinetics of a single oral dose of finerenone 10 mg 
(immediate-release tablet) in adults with mild (creatinine clearance [CLCR ] 
50-80 mL/min; n = 8), moderate (CLCR 30 to < 50 mL/min; n = 8), or severe (CLCR 
< 30 mL/min; n  =  9) renal impairment with those in adults with normal renal 
function (CLCR > 80 mL/min; n  = 8) over 96 hours postdose. Exposure to 
finerenone was not affected by mild renal impairment. In participants with 
moderate or severe renal impairment, exposure to finerenone was increased 
compared with those with normal renal function (increase in area under the curve 
for unbound finerenone, 57.1% [outlier excluded] and 46.5%, respectively), with 
moderate to high interindividual variability. Renal impairment had no consistent 
effect on the maximum plasma concentration, Cmax (differences in Cmax for 
unbound finerenone of +12% and -7% with moderate [outlier excluded] and severe 
impairment vs normal renal function, respectively). Renal elimination of 
finerenone is minimal. However, changes in exposure may occur because of the 
effects of renal impairment on nonrenal routes of elimination.